Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly M Chin

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
ERJ Open Research|January 23, 2023
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertensionJ Gerry Coghlan, Sean Gaine, Richard Channick, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 5, 2018
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 studyAdaani Frost, Munir Janmohamed, Jason S Fritz, et al.
Drugs - Real World Outcomes|January 12, 2026
Real-World Experience with Selexipag in Patients with Pulmonary Arterial Hypertension: Treatment Patterns and Outcomes across Baseline Risk Strata (SPHERE and EXPOSURE Studies)Pilar Escribano Subias, Murali M Chakinala, Kelly M Chin, et al.
The New England Journal of Medicine|December 25, 2015
Selexipag for the Treatment of Pulmonary Arterial HypertensionOlivier Sitbon, Richard Channick, Kelly M Chin, et al.
Journal of the American College of Cardiology|February 16, 2018
Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for MortalityVallerie V McLaughlin, Marius M Hoeper, Richard N Channick, et al.
American Journal of Respiratory and Critical Care Medicine|May 8, 2026
Circulating Biomarker Results From a Phase 2 Study of Seralutinib in Pulmonary Arterial HypertensionRobin Osterhout, Athénaïs Boucly, Raymond L Benza, et al.
Advances in Therapy|August 11, 2025
Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension StudyOlivier Sitbon, Sandeep Sahay, Pilar Escribano Subías, et al.
The Lancet. Respiratory Medicine|May 5, 2024
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trialRobert P Frantz, Vallerie V McLaughlin, Sandeep Sahay, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
ERJ Open Research|January 23, 2023
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertensionJ Gerry Coghlan, Sean Gaine, Richard Channick, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 5, 2018
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 studyAdaani Frost, Munir Janmohamed, Jason S Fritz, et al.
Drugs - Real World Outcomes|January 12, 2026
Real-World Experience with Selexipag in Patients with Pulmonary Arterial Hypertension: Treatment Patterns and Outcomes across Baseline Risk Strata (SPHERE and EXPOSURE Studies)Pilar Escribano Subias, Murali M Chakinala, Kelly M Chin, et al.
The New England Journal of Medicine|December 25, 2015
Selexipag for the Treatment of Pulmonary Arterial HypertensionOlivier Sitbon, Richard Channick, Kelly M Chin, et al.
Journal of the American College of Cardiology|February 16, 2018
Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for MortalityVallerie V McLaughlin, Marius M Hoeper, Richard N Channick, et al.
American Journal of Respiratory and Critical Care Medicine|May 8, 2026
Circulating Biomarker Results From a Phase 2 Study of Seralutinib in Pulmonary Arterial HypertensionRobin Osterhout, Athénaïs Boucly, Raymond L Benza, et al.
Advances in Therapy|August 11, 2025
Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension StudyOlivier Sitbon, Sandeep Sahay, Pilar Escribano Subías, et al.
The Lancet. Respiratory Medicine|May 5, 2024
Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trialRobert P Frantz, Vallerie V McLaughlin, Sandeep Sahay, et al.
Pageof 7